Combination therapy in a transgenic model of Alzheimer's disease

Experimental Neurology

Volumn 250, Issue , 2013, Pages 228-238

  Aytan, Nurgul ^a,b   Choi, Ji Kyung ^c,d   Carreras, Isabel ^a,b   Kowall, Neil W ^a,b   Jenkins, Bruce G ^c,d   Dedeoglu, Alpaslan ^a,b,c,d  

^a VA BOSTON HEALTHCARE SYSTEM   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Alzheimer's disease; Magnetic resonance spectroscopy; R flurbiprofen; Scyllo inositol

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; FLURBIPROFEN; INOSITOL DERIVATIVE; SCYLLOINOSITOL; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID NEUROPATHY; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; COGNITION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; HIPPOCAMPUS; MAZE TEST; MEMORY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ALZHEIMER'S DISEASE; MAGNETIC RESONANCE SPECTROSCOPY; R-FLURBIPROFEN; SCYLLO-INOSITOL;

ALZHEIMER DISEASE; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; COGNITION; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLURBIPROFEN; INOSITOL; MAGNETIC RESONANCE SPECTROSCOPY; MEMORY; MICE; MICE, TRANSGENIC; NEUROPROTECTIVE AGENTS;

EID: 84886296169     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2013.10.001     Document Type: Article

References (32)

1. Choi J.K., Carreras I., Dedeoglu A., Jenkins B.G. Detection of increased scyllo-inositol in brain with magnetic resonance spectroscopy after dietary supplementation in Alzheimer's disease mouse models. Neuropharmacology 2010, 59(4-5):353-357. (pii:S0028-3908(10)00087-0). 10.1016/j.neuropharm.2010.03.011.
2. Choi J.K., Jenkins B.G., Carreras I., Kaymakcalan S., Cormier K., Kowall N.W., Dedeoglu A. Anti-inflammatory treatment in AD mice protects against neuronal pathology. Exp. Neurol. 2010, 223(2):377-384. 10.1016/j.expneurol.2009.07.032.
3. Czirr E., Leuchtenberger S., Dorner-Ciossek C., Schneider A., Jucker M., Koo E.H., Pietrzik C.U., Baumann K., Weggen S. Insensitivity to Abeta42-lowering nonsteroidal anti-inflammatory drugs and gamma-secretase inhibitors is common among aggressive presenilin-1 mutations. J. Biol. Chem. 2007, 282(34):24504-24513. 10.1074/jbc.M700618200.
4. Dedeoglu A., Choi J.K., Cormier K., Kowall N.W., Jenkins B.G. MRS analysis of AD mouse brain that express mutant human APP shows altered neurochemical profile. Brain Res. 2004, 1012(1-2):60-65. 10.1016/j.brainres.2004.02.079.
5. Eriksen J.L., Sagi S.A., Smith T.E., Weggen S., Das P., McLendon D.C., Ozols V.V., Jessing K.W., Zavitz K.H., Koo E.H., Golde T.E. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J. Clin. Invest. 2003, 112(3):440-449. (112/3/440 [pii]). 10.1172/JCI18162.
6. Fenili D., Brown M., Rappaport R., McLaurin J. Properties of scyllo-inositol as a therapeutic treatment of AD-like pathology. J. Mol. Med. (Berl.) 2007, 85(6):603-611. 10.1007/s00109-007-0156-7.
7. Gasparini L., Ongini E., Wilcock D., Morgan D. Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease. Brain Res. Brain Res. Rev. 2005, 48(2):400-408. 10.1016/j.brainresrev.2004.12.029.
8. Geisslinger G., Lotsch J., Menzel S., Kobal G., Brune K. Stereoselective disposition of flurbiprofen in healthy subjects following administration of the single enantiomers. Br. J. Clin. Pharmacol. 1994, 37(4):392-394.
9. Green R.C., Schneider L.S., Amato D.A., Beelen A.P., Wilcock G., Swabb E.A., Zavitz K.H. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 2009, 302(23):2557-2564. 10.1001/jama.2009.1866.
10. Griffith H.R., den Hollander J.A., Stewart C.C., Evanochko W.T., Buchthal S.D., Harrell L.E., Zamrini E.Y., Brockington J.C., Marson D.C. Elevated brain scyllo-inositol concentrations in patients with Alzheimer's disease. NMR Biomed. 2007, 20(8):709-716. 10.1002/nbm.1132.
11. Hillmann A., Hahn S., Schilling S., Hoffmann T., Demuth H.U., Bulic B., Schneider-Axmann T., Bayer T.A., Weggen S., Wirths O. No improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer's disease. Neurobiol. Aging 2012, 33(4):833. (e39-50). 10.1016/j.neurobiolaging.2011.08.006.
12. Veld B.A., Ruitenberg A., Hofman A., Launer L.J., van Duijn C.M., Stijnen T., Breteler M.M., Stricker B.H. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N. Engl. J. Med. 2001, 345(21):1515-1521. 10.1056/NEJMoa010178.
13. Jantzen P.T., Connor K.E., DiCarlo G., Wenk G.L., Wallace J.L., Rojiani A.M., Coppola D., Morgan D., Gordon M.N. Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J. Neurosci. 2002, 22(6):2246-2254. (doi:22/6/2246 [pii]).
14. Koffie R.M., Meyer-Luehmann M., Hashimoto T., Adams K.W., Mielke M.L., Garcia-Alloza M., Micheva K.D., Smith S.J., Kim M.L., Lee V.M., Hyman B.T., Spires-Jones T.L. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(10):4012-4017. 10.1073/pnas.0811698106.
15. Kowall N.W., Hantraye P., Brouillet E., Beal M.F., McKee A.C., Ferrante R.J. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. Neuroreport 2000, 11(1):211-213.
16. Kukar T., Prescott S., Eriksen J.L., Holloway V., Murphy M.P., Koo E.H., Golde T.E., Nicolle M.M. Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci. 2007, 8:54. 10.1186/1471-2202-8-54.
17. McKee A.C., Carreras I., Hossain L., Ryu H., Klein W.L., Oddo S., LaFerla F.M., Jenkins B.G., Kowall N.W., Dedeoglu A. Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res. 2008, 1207:225-236. 10.1016/j.brainres.2008.01.095.
18. McLaurin J., Golomb R., Jurewicz A., Antel J.P., Fraser P.E. Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta-induced toxicity. J. Biol. Chem. 2000, 275(24):18495-18502. 10.1074/jbc.M906994199.
19. McLaurin J., Kierstead M.E., Brown M.E., Hawkes C.A., Lambermon M.H., Phinney A.L., Darabie A.A., Cousins J.E., French J.E., Lan M.F., Chen F., Wong S.S., Mount H.T., Fraser P.E., Westaway D., St George-Hyslop P. Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat. Med. 2006, 12(7):801-808. 10.1038/nm1423.
20. Mlynarik V., Cacquevel M., Sun-Reimer L., Janssens S., Cudalbu C., Lei H., Schneider B.L., Aebischer P., Gruetter R. Proton and phosphorus magnetic resonance spectroscopy of a mouse model of Alzheimer's disease. J. Alzheimers Dis. 2012, 31(Suppl. 3):S87-S99. (pii:C33W542181717678). 10.3233/JAD-2012-112072.
21. Oakley H., Cole S.L., Logan S., Maus E., Shao P., Craft J., Guillozet-Bongaarts A., Ohno M., Disterhoft J., Van Eldik L., Berry R., Vassar R. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006, 26(40):10129-10140.
22. Page R.M., Baumann K., Tomioka M., Perez-Revuelta B.I., Fukumori A., Jacobsen H., Flohr A., Luebbers T., Ozmen L., Steiner H., Haass C. Generation of Abeta38 and Abeta42 is independently and differentially affected by familial Alzheimer disease-associated presenilin mutations and gamma-secretase modulation. J. Biol. Chem. 2008, 283(2):677-683. 10.1074/jbc.M708754200.
23. Sabuncu M.R., Buckner R.L., Smoller J.W., Lee P.H., Fischl B., Sperling R.A., Alzheimer's Disease Neuroimaging I. The association between a polygenic Alzheimer score and cortical thickness in clinically normal subjects. Cereb. Cortex 2012, 22(11):2653-2661. 10.1093/cercor/bhr348.
24. Salloway S., Sperling R., Keren R., Porsteinsson A.P., van Dyck C.H., Tariot P.N., Gilman S., Arnold D., Abushakra S., Hernandez C., Crans G., Liang E., Quinn G., Bairu M., Pastrak A., Cedarbaum J.M. A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology 2011, 77(13):1253-1262. 10.1212/WNL.0b013e3182309fa5.
25. Selkoe D.J. Alzheimer disease: mechanistic understanding predicts novel therapies. Ann. Intern. Med. 2004, 140(8):627-638. (doi:140/8/627 [pii]).
26. Selkoe D.J. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav. Brain Res. 2008, 192(1):106-113. 10.1016/j.bbr.2008.02.016.
27. Shankar G.M., Li S., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A., Regan C.M., Walsh D.M., Sabatini B.L., Selkoe D.J. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 2008, 14(8):837-842. 10.1038/nm1782.
28. Townsend M., Cleary J.P., Mehta T., Hofmeister J., Lesne S., O'Hare E., Walsh D.M., Selkoe D.J. Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Ann. Neurol. 2006, 60(6):668-676. 10.1002/ana.21051.
29. Walsh D.M., Selkoe D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004, 44(1):181-193. (pii:S0896627304006038). 10.1016/j.neuron.2004.09.010.
30. Wechter W.J., Bigornia A.E., Murray E.D., Jee W.S. Chiral pharmacokinetics of Rac-flurbiprofen and pharmacodynamics of anabolic bone response in the normal rat. Chirality 1994, 6(6):457-459. 10.1002/chir.530060602.
31. Weggen S., Eriksen J.L., Das P., Sagi S.A., Wang R., Pietrzik C.U., Findlay K.A., Smith T.E., Murphy M.P., Bulter T., Kang D.E., Marquez-Sterling N., Golde T.E., Koo E.H. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001, 414(6860):212-216. 10.1038/35102591.
32. Weggen S., Eriksen J.L., Sagi S.A., Pietrzik C.U., Ozols V., Fauq A., Golde T.E., Koo E.H. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. J. Biol. Chem. 2003, 278(34):31831-31837. 10.1074/jbc.M303592200.